The U.S. Food and Drug Administration (FDA) has asked for more data from clinical trials that tested Dupixent (dupilumab) in people with chronic obstructive pulmonary disease (COPD), Regeneron Pharmaceuticals, one of the therapy’s developers, announced during a company webcast. The requested data pertains to subgroup analyses from two…
A research team at The Lundquist Institute has been awarded a four-year grant to develop a wearable biosensor that can monitor continuously the risk of acute exacerbations by analyzing the sweat of people with chronic obstructive pulmonary disease (COPD). The grant, worth more than $2.6 million, was awarded by…
People with diets rich in ultra-processed foods, those typically loaded with harmful additives and preservatives, have a 26% higher risk of dying from chronic obstructive pulmonary disease (COPD), a study drawing on U.S. data reports. Such a daily diet — one roughly consisting of more than 40% of ultra-processed…
A new campaign will highlight the ways certain jobs, including those related to mining, agriculture, and manufacturing, can increase the risk of developing chronic obstructive pulmonary disease (COPD). Long-term exposure to dust, chemicals, fumes, and vapors in the workplace may all lead to COPD, said the American Lung…
Permanent night shift work is associated with a nearly 50% higher risk of developing chronic obstructive pulmonary disease (COPD) relative to day work, according to a large study of U.K. data. The risk of COPD was even higher among permanent night shift workers with high genetic susceptibility to the…
Apogee Therapeutics has begun dosing healthy volunteers in a Phase 1 clinical trial of APG808, the company’s anti-inflammatory injection therapy for chronic obstructive pulmonary disease (COPD), asthma, and other inflammatory disorders. “Launching our second clinical program, ahead of initial timeline expectations, brings us one step closer to providing…
Out-of-pocket costs for AstraZeneca’s inhaled respiratory therapies — most of which are used for chronic obstructive pulmonary disease (COPD) — will be capped at $35 per month for eligible patients in the U.S. starting in June, the company announced in a press release. This cap, likely to…
A Phase 3 clinical trial assessing the potential of triple-combination Breztri Aerosphere (budesonide/glycopyrronium/formoterol fumarate) to improve cardiopulmonary outcomes in people with chronic obstructive pulmonary disease (COPD) is opening at sites worldwide, AstraZeneca, which markets the inhaled therapy, announced. The THARROS study (NCT06283966) is expected to enroll up…
A first patient has been treated in a pivotal clinical trial of Pulmonx’s AeriSeal System, testing its ability to limit collateral ventilation in people with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). These patients currently are precluded from using the company’s minimally invasive…
The first patient has been dosed in a Phase 2a clinical trial testing ReAlta Life Sciences’ RLS-0071 in adults with chronic obstructive pulmonary disease (COPD) who are experiencing acute exacerbations, or sudden symptom worsening. The trial (NCT06175065) will evaluate the safety of RLS-0071 versus a placebo in…
Get regular updates to your inbox.